Results 151 to 160 of about 296,448 (281)

Pooled safety results across phase 3 randomized trials of intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. [PDF]

open access: yesArthritis Res Ther, 2022
Husni ME   +8 more
europepmc   +1 more source

Economic burden of hidradenitis suppurativa based on healthcare resource utilization: German claims data analysis

open access: yesJDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and Objectives Hidradenitis suppurativa (HS) is a chronic, debilitating skin disease affecting approximately 0.1% of the German population. Patients with HS require substantial healthcare resource utilization. This study aimed to assess the economic burden associated with HS in Germany.
Falk G. Bechara   +7 more
wiley   +1 more source

Real-Life Retention Rates and Reasons for Switching of Biological DMARDs in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis. [PDF]

open access: yesFront Med (Lausanne), 2021
Bhushan V   +11 more
europepmc   +1 more source

Impact of adalimumab treatment on impairment of non‐professional activities in psoriasis patients

open access: yesJDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and objectives Psoriasis can result in reduced quality of life, work productivity loss, and a significant restriction in non‐professional activities. This study investigates the effects of long‐term treatment with adalimumab regarding work ability, non‐professional activities, and health‐related quality of life in a large real‐word ...
Georgios Kokolakis   +4 more
wiley   +1 more source

Vascularized joint‐on‐a‐chip: A paradigm shift for arthritis pathophysiology and clinical treatment

open access: yes
Rheumatology &Autoimmunity, EarlyView.
Danli Cui   +6 more
wiley   +1 more source

PeakPASI as a marker of maximum psoriasis severity: a single‐center, cross‐sectional retrospective and questionnaire‐based study

open access: yesJDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background The Psoriasis Area and Severity Index (PASI) is the standard measure for psoriasis severity but reflects only a single time point and may underestimate long‐term disease burden. To assess whether the highest‐ever recorded PASI (PeakPASI) can serve as a marker of historical disease severity and correlate with treatment burden and ...
Simran Wilkhoo   +6 more
wiley   +1 more source

Effectiveness of Golimumab as Second Anti-TNFα Drug in Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Axial Spondyloarthritis in Italy: GO-BEYOND, a Prospective Real-World Observational Study. [PDF]

open access: yesJ Clin Med, 2022
D'Angelo S   +30 more
europepmc   +1 more source

S1 Guideline: Therapy of generalized pustular psoriasis

open access: yesJDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary The S1 guideline “Therapy of generalized pustular psoriasis (GPP)” is a German guideline developed in accordance with the criteria of the AWMF. The full version addresses clinical presentation, pathogenesis, diagnosis and differential diagnosis, comorbidities, and therapy.
Rotraut Mößner   +17 more
wiley   +1 more source

Psoriatic arthritis mutilans [PDF]

open access: yesQJM: An International Journal of Medicine, 2020
J Samanta, A Chattopadhyay, A Sharma
openaire   +2 more sources

Home - About - Disclaimer - Privacy